• 1. A gold immunochromatographic assay for the rapid and simultaneous detection of fifteen β-lactams
  Yanni Chen,Yongwei Wang,Liqiang Liu,Xiaoling Wu,Liguang Xu,Hua Kuang,Aike Li,Chuanlai Xu Nanoscale 2015 7 16381
• 2. One-pot synthesis of superabsorbent hybrid hydrogels based on methacrylamide gelatin and polyacrylamide. Effortless control of hydrogel properties through composition design
  Andrada Serafim,Catalin Tucureanu,Daniela-Geta Petre,Diana-Maria Dragusin,Aurora Salageanu,Sandra Van Vlierberghe,Peter Dubruel,Izabela-Cristina Stancu New J. Chem. 2014 38 3112
• 3. Dual detection of nafcillin using a molecularly imprinted polymer-based platform coupled to thermal and fluorescence read-out
  Alexander D. Hudson,Oliver Jamieson,Robert D. Crapnell,Knut Rurack,Thais C. C. Soares,Francesco Mecozzi,Alex Laude,Jonas Gruber,Katarina Novakovic,Marloes Peeters Mater. Adv. 2021 2 5105
• 4. Microtoxicology by microfluidic instrumentation: a review
  Jialan Cao,Charmi Chande,J. Michael K?hler Lab Chip 2022 22 2600
• 5. The electrophoretic separation of penicillins and penicilloic acids
  A. H. Thomas,R. A. Broadbridge Analyst 1970 95 459

• Solvents and Organic Chemicals Organic Compounds Organic acids and derivatives Carboxylic acids and derivatives Amino acids, peptides, and analogues Amino acids and derivatives
• Pesticide Chemicals Pesticide Active Ingredients Standard Substances
• Pharmaceutical and Biochemical Products Pharmaceutical Active Ingredients Standard Substances

Introduction to Nafcillin Sodium Monohydrate (CAS No. 7177-50-6)

Nafcillin Sodium Monohydrate, with the chemical name 6-(3-amino-4-hydroxyphenyl)-1,4-dimethyl-4-oxo-1,4-thiazetidin-3-carboxylic acid sodium salt monohydrate, is a well-established antibiotic belonging to the penicillin class. Its CAS number, 7177-50-6, uniquely identifies it in the chemical and pharmaceutical industries. This compound has been widely utilized in the treatment of bacterial infections, particularly those caused by penicillinase-producing staphylococci. The monohydrate form indicates that the compound crystallizes with one molecule of water, which can influence its solubility and stability.

The development of Nafcillin Sodium Monohydrate was a significant milestone in antibiotic therapy, especially during the latter half of the 20th century. Its ability to resist degradation by beta-lactamase enzymes produced by certain bacteria made it a crucial weapon against resistant strains. Over the years, extensive research has been conducted to optimize its pharmacokinetic properties and explore novel therapeutic applications.

In recent years, advancements in microbiology and pharmacology have led to a deeper understanding of how Nafcillin Sodium Monohydrate interacts with bacterial cell walls. Studies have revealed that its mechanism of action involves inhibiting the synthesis of peptidoglycan, a critical component of bacterial cell walls, thereby leading to cell lysis and death. This mechanism has been further refined through structural modifications aimed at enhancing efficacy and reducing side effects.

One of the most compelling aspects of Nafcillin Sodium Monohydrate is its role in treating methicillin-resistant Staphylococcus aureus (MRSA) infections. While MRSA has become increasingly resistant to many antibiotics, Nafcillin Sodium Monohydrate remains effective against susceptible strains. Recent clinical trials have demonstrated its efficacy when used in combination with other antibiotics, providing a promising strategy for managing multidrug-resistant infections.

The pharmacokinetic profile of Nafcillin Sodium Monohydrate has been extensively studied to ensure optimal dosing regimens. Its relatively short half-life necessitates frequent administration, which can be challenging for patients. However, novel formulations such as extended-release versions are being developed to improve patient compliance and convenience. These formulations aim to maintain therapeutic levels in the bloodstream for longer periods, reducing the frequency of dosing while maintaining efficacy.

From a chemical perspective, the structure of Nafcillin Sodium Monohydrate (CAS No. 7177-50-6) is characterized by a beta-lactam ring fused with a thiazetidine ring. This unique structural motif contributes to its potent antibacterial activity. The sodium salt form enhances solubility, making it more suitable for intravenous administration. The monohydrate designation indicates the presence of one water molecule in its crystal lattice, which can affect its physical properties such as melting point and solubility.

Recent research has also explored the potential applications of Nafcillin Sodium Monohydrate in veterinary medicine. Its effectiveness against Gram-positive bacteria makes it a viable option for treating infections in livestock and companion animals. Studies have shown that it can be used to manage infections caused by Staphylococcus aureus and other resistant pathogens in animals, contributing to improved animal health and welfare.

The safety profile of Nafcillin Sodium Monohydrate has been well-documented through decades of clinical use. Common side effects include mild gastrointestinal disturbances such as nausea and diarrhea. More serious adverse effects are rare but may include allergic reactions ranging from mild rashes to anaphylaxis. Patients with a history of penicillin allergy should use this medication with caution under medical supervision.

Manufacturing processes for Nafcillin Sodium Monohydrate have evolved significantly over time to ensure high purity and consistency. Modern synthetic routes involve multi-step organic reactions starting from readily available precursors such as phenylacetic acid derivatives. Advances in biocatalysis have also enabled more efficient production methods, reducing environmental impact while maintaining high yields.

The future prospects for Nafcillin Sodium Monohydrate are promising, particularly in light of rising antibiotic resistance rates worldwide. Ongoing research aims to develop new derivatives with enhanced properties such as broader spectrum activity or improved pharmacokinetics. Additionally, combination therapies involving Nafcillin Sodium Monohydrate with other antibiotics or non-pharmacological agents are being explored to combat resistant strains more effectively.

In conclusion,Nafcillin Sodium Monohydrate (CAS No. 7177-50-6) remains a cornerstone in antibiotic therapy despite challenges posed by increasing bacterial resistance. Its unique structure, potent activity against resistant pathogens, and well-established safety profile make it an invaluable tool in modern medicine. Continued research and development efforts will further enhance its therapeutic potential and ensure its relevance in addressing global health challenges.

• 147-52-4((2S,5R,6R)-6-(2-ethoxynaphthalene-1-amido)-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo3.2.0heptane-2-carboxylic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)